AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Cardiol Therapeutics Inc Class A (NASDAQ:CRDL)
1.06 USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.06 |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 1.695/0.880 |
| EBITDA (in USD) | -34.278M |
| PE Ratio | -- |
| Volume | 257291 |
| Diluted Eps TTM | -0.28 |
| Total Assets (in USD) | 23.62M |
|---|---|
| Total Liabilities (in USD) | 5.742M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 21.417M |
| Market Cap (in USD) | 182.039 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | 0.079M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Employees: 18
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. David G. Elsley M.B.A., MBA | Pres, CEO & Director | NA |
| 2. | Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, M.B.A., MBA | CFO, Corp. Sec. & Director | NA |
| 3. | Mr. Bernard Lim B.Sc. | Chief Operating Officer | NA |
| 4. | Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer & Head of R&D | 1962 |
| 5. | Trevor Burns | Investor Relations | NA |
| 6. | Mr. David G. Elsley MBA | President, CEO & Director | NA |
| 7. | Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA | CFO, Corporate Secretary & Director | NA |
| 8. | Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer & Head of Research & Development | 1962 |
| 9. | Mr. Christopher J. Waddick C.A., C.M.A., CPA, MBA | CFO, Corporate Secretary & Director | NA |
| 10. | Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer and Head of Research & Development | 1962 |
Peers
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ZTS
Zoetis Inc |
+1.450 1.877% | 77.73 | 40.180 | 30.960 | 10.675 | 17.597 | 11.271 | 26.180 |
|
MKKGY
Merck KGaA ADR |
+0.090 0.296% | 30.45 | 21.250 | 14.925 | 3.099 | 2.143 | 3.605 | 12.978 |
|
MKGAF
MERCK Kommanditgesellschaft auf Aktien |
+4.000 2.612% | 157.12 | 21.730 | 14.948 | 3.159 | 2.147 | 3.562 | 12.822 |
|
GALDY
GALDERMA GROUP AG |
-0.330 0.763% | 43.55 | 74.210 | 41.667 | 8.636 | 5.553 | 9.151 | 42.220 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -33.819M | -36.677M | -21.223M | -30.931M | -31.638M |
| Minority Interest | - | - | - | - | - |
| Net Income | -33.819M | -36.677M | -21.223M | -30.931M | -31.638M |
| Selling General Administrative | 20.196M | 26.265M | 15.561M | 22.374M | 27.873M |
| Gross Profit | - | - | -0.187M | - | 0.079M |
| Reconciled Depreciation | 0.102M | 0.373M | 0.24M | 0.22M | 0.22M |
| Ebit | -34.316M | -40.277M | -21.223M | -50.339M | -45.473M |
| Ebitda | -34.214M | -40.115M | -21.035M | -50.119M | -45.253M |
| Depreciation And Amortization | 0.102M | 0.162M | 0.187M | 0.22M | 0.22M |
| Operating Income | -34.316M | -40.277M | -22.473M | -50.339M | -45.473M |
| Other Operating Expenses | 34.316M | 40.277M | 22.473M | 41.336M | 38.744M |
| Interest Expense | - | - | - | - | 0M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 0.726M | 1.193M | 2.175M | 1.238M | 0.106M |
| Net Interest Income | 0.726M | 1.193M | 2.175M | 1.238M | 0.106M |
| Income Tax Expense | - | - | 0M | -10.241M | -6.914M |
| Total Revenue | 0M | 0M | 0M | 0M | 0.079M |
| Total Operating Expenses | 34.316M | 40.277M | 22.286M | 41.336M | 38.744M |
| Cost Of Revenue | - | - | 0.187M | - | - |
| Total Other Income Expense Net | 0.497M | 3.599M | 1.25M | 9.168M | 6.921M |
| Net Income From Continuing Ops | -33.819M | -36.677M | -28.006M | -30.931M | -31.638M |
| Net Income Applicable To Common Shares | - | - | - | -30.931M | -31.638M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 23.62M | 31.864M | 36.701M | 62.029M | 87.876M |
| Intangible Assets | - | - | 0.21M | 0.295M | 0.379M |
| Other Current Assets | 1.859M | 0.727M | 0.941M | - | - |
| Total Liab | 5.742M | 7.135M | 8.454M | 9.827M | 11.638M |
| Total Stockholder Equity | 17.878M | 24.728M | 28.247M | 52.202M | 76.238M |
| Other Current Liab | 5.617M | 6.977M | 0.655M | 9.754M | 11.52M |
| Common Stock | 201.866M | 179.335M | 148.519M | 147.545M | 142.919M |
| Capital Stock | 201.866M | 179.335M | - | 147.545M | 142.919M |
| Retained Earnings | -213.073M | -179.254M | -142.577M | -114.449M | -83.518M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | 0M | - | - |
| Cash | 21.417M | 30.58M | 34.87M | 59.47M | 83.899M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 5.655M | 7.01M | 8.295M | 9.805M | 11.565M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -21.291M | -30.421M | -34.696M | -59.397M | -83.781M |
| Short Term Debt | 0.038M | 0.033M | 0.016M | 0.05M | 0.045M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 0.126M | 0.159M | 0.174M | 0.073M | 0.118M |
| Other Stockholder Equity | 29.084M | 24.647M | 18.786M | 19.105M | 16.837M |
| Property Plant Equipment | - | - | - | 0.296M | 0.356M |
| Total Current Assets | 23.502M | 31.668M | 36.153M | 61.438M | 87.14M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | 0.062M | - | - |
| Net Receivables | 0.226M | 0.362M | 0.28M | 0.48M | 0.407M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | 0.339M |
| Accounts Payable | - | 6.977M | 7.625M | 9.334M | 4.141M |
| Accumulated Other Comprehensive Income | - | - | 3.518M | - | - |
| Non Currrent Assets Other | - | - | -0M | - | - |
| Non Current Assets Total | 0.118M | 0.196M | 0.547M | 0.591M | 0.736M |
| Capital Lease Obligations | 0.126M | 0.159M | - | 0.073M | 0.118M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | - | -0.021M | -0.101M | -0.075M | -0.013M |
| Total Cashflows From Investing Activities | -0.024M | -0.021M | -0.064M | -0.075M | -0.013M |
| Total Cash From Financing Activities | 15.54M | 18.84M | -0.055M | -0.054M | 93.438M |
| Net Income | -33.819M | -36.677M | -28.128M | -30.931M | -31.638M |
| Change In Cash | -9.163M | -4.352M | -24.538M | -24.429M | 69.874M |
| Begin Period Cash Flow | 30.58M | 34.932M | 59.47M | 83.899M | 14.025M |
| End Period Cash Flow | 21.417M | 30.58M | 34.932M | 59.47M | 83.899M |
| Total Cash From Operating Activities | -23.855M | -25.061M | -25.18M | -27.22M | -23.551M |
| Depreciation | 0.102M | 0.373M | 0.248M | 0.22M | 0.22M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | 0M | 0M | 0.018M |
| Sale Purchase Of Stock | - | - | - | - | - |
| Other Cashflows From Financing Activities | -0.477M | -2.474M | 0.055M | -0.075M | 9.406M |
| Capital Expenditures | 0.024M | 0.021M | 0.064M | 0.075M | 0.013M |
| Change In Working Capital | -0.733M | -0.932M | -0.546M | 5.748M | 0.077M |
| Other Non Cash Items | -0.105M | -2.103M | -0.911M | -7.271M | -0.707M |
| Free Cash Flow | -23.879M | -25.082M | -25.245M | -27.295M | -23.564M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Blackstone Alternative Multi-Strategy I | 8 months ago | 100 |
| 2. | DFA Canadian Core Equity Class F | 2 years ago | 11500 |
| 3. | Fidelity Nasdaq Composite Index | 3 months ago | 52435 |
| 4. | Ninepoint Cannabis & Alt Health S A | 4 months ago | 12500 |
| 5. | Ninepoint Alternative Health A | 4 months ago | 12500 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Tejara Capital Ltd | 5 months ago | 5130122 |
| 2. | AdvisorShares Investments, LLC | 5 months ago | 597977 |
| 3. | Bank of America Corp | 8 months ago | 551053 |
| 4. | INTEGRITY ALLIANCE, LLC. | 5 months ago | 435025 |
| 5. | Two Sigma Investments LLC | 5 months ago | 406935 |
| 6. | The Goldman Sachs Group Inc | 5 months ago | 328500 |
| 7. | Mmcap International Inc. Spc | 5 months ago | 208950 |
| 8. | Susquehanna International Group, LLP | 5 months ago | 203726 |
| 9. | Morgan Stanley - Brokerage Accounts | 8 months ago | 156331 |
| 10. | Marshall Wace Asset Management Ltd | 5 months ago | 151517 |
| 11. | Virtu Financial LLC | 8 months ago | 144062 |
| 12. | Sheets Smith Investment Management | 8 months ago | 142097 |
| 13. | Summit Financial LLC | 5 months ago | 104059 |
| 14. | Knoll Capital Management LP | 5 months ago | 100000 |
| 15. | We Are One Seven, LLC | 5 months ago | 100000 |
| 16. | 1832 Asset Management L.P | 5 months ago | 100000 |
| 17. | UBS Group AG | 8 months ago | 53490 |
| 18. | Geode Capital Management, LLC | 5 months ago | 52435 |
| 19. | Marble Harbor Investment Counsel, LLC | 5 months ago | 39900 |
| 20. | Jane Street Group LLC | 5 months ago | 39828 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...